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Abstract  
Central nervous system injury, specifically traumatic brain and spinal cord injury, can have 
significant long lasting effects. There are no comprehensive treatments to combat the 
injury and sequalae of events that occurring following a central nervous system trauma. 
Herein we discuss the potential for the epothilone family of microtubule stabilizing agents 
to improve outcomes following experimentally induced trauma. These drugs, which 
are able to cross the blood-brain barrier, may hold great promise for the treatment of 
central nervous system trauma and the current literature presents the extensive range of 
beneficial effects these drugs may have following trauma in animal models. Importantly, 
the effect of the epothilones can vary and our most recent contributions to this field 
indicate that the efficacy of epothilones following traumatic brain injury is dependent 
upon the age of the animals. Therefore, we present a case for a greater emphasis to be 
placed upon age when using an intervention aimed at neural regeneration and highlight 
the importance of tailoring the therapeutic regime in the clinic to the age of the patient to 
promote improved patient outcomes.
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Traumatic brain and spinal cord injuries continue to be a 
leading cause of death and disability in developed nations 
(Stocchetti and Zanier, 2016). This trauma can result in 
primary damage and complex secondary pathologies, which 
can cause prolonged or life-long motor and/or cognitive 
impairments. There are currently no available therapeutics 
that are able to prevent, minimize or reverse the deficits 
that develop following central nervous system (CNS) trauma. 
Effective therapeutic strategies are not being discovered fast 
enough and many promising drugs in the preclinical setting 
are not proving effective in clinical trial. A recurrent theme 
over the last decade has been to focus on why so many 
promising new therapeutics are failing to jump the gap from 
bench to bedside. One possible limitation to preclinical trials, 
that may not be accounted for appropriately, is the effect of 
age on the heterogeneity of symptoms and functional deficits 
following a CNS insult (Sun et al., 2020). Here we examine the 
evidence for a promising therapy for treating CNS trauma, the 
epothilones, which have potent neuronal and non-neuronal 
cell actions principally through microtubule stabilization, and 
propose that the efficacy of these drugs and likelihood of 
success in translating to the clinic may depend upon stratifying 
for age at insult.
A consequence of CNS trauma is neuronal cell loss and axonal 
injury, and the activation and reaction of glial populations 
(Spain et al., 2010; Wang and Ma, 2010; Greer et al., 2011; 
Hassannejad et al., 2019). Following injury microglia, 
oligodendroglial precursors, meningeal cells and astrocytes 
concentrate within the injury site. These cells can have both 
favorable and detrimental effects on the neuronal regenerative 
response (Ng and Lee, 2019). The formation of the glial scar 
presents a chemical and physical barrier to stop the spread 
of the injury, while conversely inhibiting regeneration of 
disconnected axons (Fawcett and Asher, 1999). Axons are 
particularly vulnerable to structural injury due to their relative 
long length and size. Injury-induced axonal degeneration can 
have devastating and far-reaching effects. In severe trauma 
axons are severed, and this disconnection can lead to a 
starvation of the post synaptic connection and disruption 
and retraction of the proximal neuron (Blennow et al., 2016). 
In mild to moderate traumatic brain injury, axons are often 
subtly disrupted at the time of injury, with immediate changes 
including mechanically induced alterations in permeability, 
deregulation of ionic homeostasis and compression of the 
cytoskeleton that can finally lead to disconnection (Smith 
et al., 2013). Hence, regardless of the initial injury severity 
cytoskeletal misalignment or loss and the accumulation 
or compaction of cytoskeletal components is a common 
event. The microtubule cytoskeleton has been shown to be 
particularly disrupted following structural injury: Microtubule 
alterations after injury include microtubule disruption and 
detachment with associated defects in axonal transport 
(Smith et al., 1999; Tang-Schomer et al., 2010) and the loss of 
microtubule-associated proteins such as Tau and microtubule-
associated protein 2 (Farkas and Povlishock, 2007; Bradke et 
al., 2012; Smith et al., 2013).
Systematic database searches of PubMed and Web of Science 
were performed to identify valid peer reviewed studies with 
no limitations on year of publication. Keyword terms used 
focused on CNS aging, CNS trauma, traumatic brain injury, 
Review
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
*Correspondence to: Catherine Blizzard, PhD, Catherine.Blizzard@utas.edu.au. 
https://orcid.org/0000-0002-8683-2937 (Catherine Blizzard) 
#Both authors contributed equally to this work.
How to cite this article: Clark J, Zhu Z, Chuckowree J, Dickson T, Blizzard C (2021) Efficacy of epothilones in central nervous system trauma treatment: what has 
age got to do with it? Neural Regen Res 16(1):618-620. 
NEURAL REGENERATION RESEARCH｜Vol 16｜No.4｜April 2021｜619
microtubule stabilisation, epothilones and taxanes, axonal 
regeneration and neuronal regeneration. We used a narrow 
selection criteria for this review, and other variables should be 
considered to gain a greater understanding on age dependant 
CNS trauma and therapeutic targeting.
Critical to the treatment of CNS trauma is the restoration 
of neuronal and glial function. Microtubule stabilizing 
drugs, including Food and Drug Administration approved 
taxanes and the epothilones, hold the potential to effect 
both neuronal and glial populations. Taxanes and the 
epothilones are already used at relatively high doses in the 
treatment of various cancers where, due to their hyper-
stabilization of microtubules, they act to arrest cell division 
and slow or prevent cancer cell growth (Goodin et al., 2004; 
Kolman, 2004). However, it is their action at low doses 
that holds particular promise for treating CNS injury. At 
low concentrations these same drugs can protect against 
microtubule depolarization and dissolution, and encourage 
polarization and structural stability (Brunden et al., 2010; 
Hellal et al., 2011; Sengottuvel and Fischer, 2011; Baas and 
Ahmad, 2013). This quality could be particularly beneficial 
for protecting axons following structural injury. Indeed, 
paclitaxel, one of the taxanes, has been shown to improve 
outcomes following models of nerve injury by promoting 
axonal elongation and regeneration and also reducing glial 
scar formation (Hellal et al., 2011; Sengottuvel et al., 2011). 
However, paclitaxel has poor blood-brain barrier permeability, 
making it a sub-optimal candidate for CNS delivery. The 
epothilones, a group of microtubule stabilizing compounds 
found naturally in the myxobacterium Sorangium cellulosum 
(Bollag et al., 1995), offer an attractive alternative solution. 
Numerous epothilones have now been identified, including 
Epothilone B (EpoB) and Epothlione D (EpoD), which share 
a mode of action similar to paclitaxel for the binding site on 
β-tubulin (Brunden et al., 2011). Due to their increased water 
solubility, the epothilones readily crosses the blood-brain 
barrier and can be retained within the CNS for several days 
(Andrieux et al., 2006; Cortes and Baselga, 2007; Brunden et 
al., 2012).
An exciting publication in 2015 cemented the epothilones as a 
promising therapeutic intervention following CNS injury. Using 
EpoB, administered following spinal cord injury, the authors 
convincingly demonstrated EpoB therapy led to increased 
axon outgrowth, reduced scarring and improved functional 
recovery in female rats (Ruschel et al., 2015). The axonal 
outgrowth was improved through increased microtubule 
polymerization, and consequently microtubule protrusion 
into regenerating axons. This work has been supported with 
evidence for similar efficacy of EpoD (Ruschel and Bradke, 
2018; Sandner et al., 2018), its effect on other cell types (Zhao 
et al., 2017) and other in vivo experimental models of axonal 
injury such as spinal and corneal nerve injury (Li and Wu, 2017; 
Wang et al., 2018). A positive effect has also been reported 
in EpoB administered following intracerebral hemorrhage, 
in which it restored the integrity of the nigrostriatal pathway 
neuronal circuit and improve fine motor functional recovery 
after injury in mice (Yang et al., 2018). These findings follow 
similar promising results seen in neurodegenerative disease; 
EpoD treatment resulted in improved outcomes in in vivo 
models of Parkinson’s disease (Cartelli et al., 2013), tauopathy 
and Alzheimer’s disease (Brunden et al., 2010; Zhang et al., 
2012), and schizophrenia (Andrieux et al., 2006; Fournet et 
al., 2012). However, a collection of studies also reports subtle 
or adverse effects of epothilones in some neurodegenerative 
models (Mao et al., 2017; Clark et al., 2018). This discrepancy 
in findings raises the question of why does the effect of 
epothilone administration vary across different experimental 
investigations?
Given Traumatic brain and spinal cord injuries can be acquired 
at any stage of life, age may play a critical role in outcomes 
following CNS trauma (Sun et al., 2020). Based on our recent 
studies, we propose that age is not only an important factor in 
dictating outcomes following CNS trauma, but also plays a role 
in determining the efficacy of microtubule stabilizers, such as 
EpoD, as a post injury intervention. When studying the effect 
of EpoD in vitro, we found that the vulnerability of cortical 
neurons to EpoD increased as the age of the neuron increased 
(Clark et al., 2020). These findings are in line with those of 
Jang et al. (2016), who found an age-related contribution 
in response to EpoB treatment in both cortical and dorsal 
root ganglion cells in vitro. Moreover, using an in vivo model 
of trauma (lateral fluid percussion brain injury) we have 
shown that a single peripherally administered dose of EpoD 
targeted central neurons, specifically increasing the density of 
mushroom spines on layer 5 cortical pyramidal neurons, with 
an absence of astroglial effects (Chuckowree et al., 2018). To 
add further evidence to these findings, we have previously 
investigated the protective effect of EpoD in a mouse model of 
amyotrophic lateral sclerosis (Clark et al., 2018). This therapy 
led to worse survival outcomes, greater functional deficits and 
an increase in microglial and astroglial activation at end stage–
approximately 6 months old. However, this treatment initially 
prevented motor neuron loss and axonal degeneration at 2 
months of age, suggesting that there may be a differing effect 
as either the disease progressed or the mouse aged. Together, 
these studies suggest that age may differentially impact the 
efficacy of EpoD on neuronal and glial populations. 
To directly address the effect of age on EpoD efficacy, we 
exposed young, adult and aged mice to an in vivo brain 
injury (lateral fluid percussion brain injury). We found that 
the degree of axonal degeneration as well as astrogliosis and 
microglial activation were age dependent (Zhu et al., 2020). 
Critically, we determined that EpoD administration had very 
different effects in young (1.5 months) versus adult (3 months) 
mice. In young mice, EpoD administration trended to confer 
protection from axonal degeneration. However, when the 
same dose was given to adult mice, EpoD had a detrimental 
effect – axonal degeneration in the internal capsule white 
matter tract was significantly increased. Collectively, these 
studies provide compelling evidence that age is an important 
contributor to outcomes following therapeutic intervention 
with epothilone derivatives. 
How exactly age is affecting epothilone efficacy, is not clear. 
Within the neuron, microtubules contribute to a range of 
neuronal functions including neurite outgrowth, neuronal 
polarity, axonal transport and regulating gene expression 
and signaling pathways (Dubey et al., 2015). Interestingly 
microtubule loss has not only been seen in Alzheimer ’s 
disease but can also be present in cases of normal aging (Cash 
et al., 2003). How microtubule function changes over time 
and how microtubule stabilizing agents bind remains to be 
defined. Furthermore, the mechanism of the effect of age is 
multifactorial; likely to involve glial cells (Ritzel et al., 2019; Sun 
et al., 2019; Webster et al., 2019) as well as neurons (Sun et al., 
2019). EpoD has been shown to reduce the glial scar and affect 
both fibroblasts and immune cells such as microglia following 
spinal cord injury (Ruschel et al., 2015; Mao et al., 2017). The 
function of microglia changes throughout the lifespan, and 
these alterations can exacerbate the injury response in an aged 
system (Morganti-Kossmann et al., 2019; Sun et al., 2020). This 
altered microglial response can be correlated to a decrease in 
functional recovery following injury, demonstrating the impact 
of the aging system on outcomes (Ritzel et al., 2019; Sun et al., 
2019). It is important to also note that the heterogeneity of the 
response to epothilone treatment may not be limited to ageing. 
The response of the CNS to trauma can be sex-dependent 
(Inampudi et al., 2020) – how this affects therapeutic 
intervention outcomes is largely unexplored.
In conclusion, mounting evidence in both trauma and 
neurodegenerative disease models highlights the need for 
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future studies determining how the efficacy of therapeutic 
microtubule stabilization is altered across the lifespan. 
Understanding how age contr ibutes to therapeutic 
intervention following trauma could pave the way to providing 
a more tailored therapeutic regime in the clinic that is specific 
to the age of the patient.
Author contributions: CB, JC and ZZ wrote the manuscript. JC and TD 
edited the manuscript. All authors approved the final manuscript.
Conflicts of interest: The authors declare no conflicts of interest.
Financial support: None. 
Copyright license agreement: The Copyright License Agreement has 
been signed by all authors before publication.
Plagiarism check: Checked twice by iThenticate. 
Peer review: Externally peer reviewed. 
Open access statement: This is an open access journal, and articles 
are distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 License, which allows others to remix, 
tweak, and build upon the work non-commercially, as long as appropriate 
credit is given and the new creations are licensed under the identical 
terms.
References
Andrieux A, Salin P, Schweitzer A, Bégou M, Pachoud B, Brun P, Gory-Fauré S, Kujala 
P, Suaud-Chagny M-F, Höfle G (2006) Microtubule stabilizer ameliorates synaptic 
function and behavior in a mouse model for schizophrenia. Biol Psychiatry 60:1224-
1230.
Baas PW, Ahmad FJ (2013) Beyond taxol: microtubule-based treatment of disease and 
injury of the nervous system. Brain 136:2937-2951.
Blennow K, Brody DL, Kochanek PM, Levin H, McKee A, Ribbers GM, Yaffe K, Zetterberg H 
(2016) Traumatic brain injuries. Nat Rev Dis Primers 2:16084.
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, 
Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a 
txol-like mechanism of action. Cancer Res 55:2325-2333.
Bradke F, Fawcett JW, Spira ME (2012) Assembly of a new growth cone after axotomy: the 
precursor to axon regeneration. Nat Rev Neurosci 13:183-193.
Brunden KR, Ballatore C, Lee VMY, Smith AB, Trojanowski JQ (2012) Brain-penetrant 
microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. 
Biochem Soc Trans 40:661-666.
Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AML, Iba M, James MJ, Xie SX, 
Ballatore C (2010) Epothilone D improves microtubule density, axonal integrity, and 
cognition in a transgenic mouse model of tauopathy. J Neurosci 30:13861-13866.
Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AML, Trojanowski 
JQ, Smith AB, Lee VMY (2011) The characterization of microtubule-stabilizing drugs 
as possible therapeutic agents for Alzheimer’s disease and related tauopathies. 
Pharmacol Res 63:341-351.
Cartelli D, Casagrande F, Busceti CL, Bucci D, Molinaro G, Traficante A, Passarella D, Giavini 
E, Pezzoli G, Battaglia G (2013) Microtubule alterations occur early in experimental 
parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. Sci Rep 
3:1837.
Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton 
M, Johnson AB, Paula-Barbosa M, Avíla J, Jones PK, Castellani RJ, Smith MA, Perry G 
(2003) Microtubule reduction in Alzheimer’s disease and aging is independent of τ 
filament formation. Am J Pathol 162:1623-1627.
Chuckowree JA, Zhu Z, Brizuela M, Lee KM, Blizzard CA, Dickson TC (2018) The 
microtubule-modulating drug epothilone D alters dendritic spine morphology in a 
mouse model of mild traumatic brain injury. Front Cell Neurosci 12:223.
Clark JA, Blizzard CA, Breslin MC, Yeaman EJ, Lee KM, Chuckowree JA, Dickson TC (2018) 
Epothilone D accelerates disease progression in the SOD1(G93A) mouse model of 
amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 44:590-605.
Clark JA, Chuckowree JA, Dyer MS, Dickson TC, Blizzard CA (2020) Epothilone D alters 
normal growth, viability and microtubule dependent intracellular functions of cortical 
neurons in vitro. Sci Rep 10:918.
Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: 
the epothilones. Oncologist 12:271-280.
Dubey J, Ratnakaran N, Koushika S (2015) Neurodegeneration and microtubule dynamics: 
death by a thousand cuts. Front Cell Neurosci 9:343.
Farkas O, Povlishock JT (2007) Cellular and subcellular change evoked by diffuse 
traumatic brain injury: a complex web of change extending far beyond focal damage. 
Prog Brain Res 161:43-59.
Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. Brain Res 
Bull 49:377-391.
Fournet V, Lavilléon G, Schweitzer A, Giros B, Andrieux A, Martres MP (2012) Both 
chronic treatments by epothilone D and fluoxetine increase the short-term memory 
and differentially alter the mood status of STOP/MAP6 KO mice.  J Neurochem 
123:982-996.
Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic 
activity. J Clin Oncol 22:2015-2025.
Greer JE, McGinn MJ, Povlishock JT (2011) Diffuse traumatic axonal injury in the mouse 
induces atrophy, c-Jun activation and axonal outgrowth in the axotomized neuronal 
population. J Neurosci 31:5089-5105.
Hassannejad Z, Yousefifard M, Azizi Y, Zadegan SA, Sajadi K, Sharif-Alhoseini M, Shakouri-
Motlagh A, Mokhatab M, Rezvan M, Shokraneh F, Hosseini M, Vaccaro AR, Harrop 
JS, Rahimi-Movaghar V (2019) Axonal degeneration and demyelination following 
traumatic spinal cord injury: A systematic review and meta-analysis. J Chem Neuroanat 
97:9-22.
Hellal F, Hurtado A, Ruschel J, Flynn KC, Laskowski CJ, Umlauf M, Kapitein LC, Strikis D, 
Lemmon V, Bixby J (2011) Microtubule stabilization reduces scarring and causes axon 
regeneration after spinal cord injury. Science 331:928-931.
Jang EH, Sim A, Im SK, Hur EM (2016) Effects of microtubule stabilization by epothilone B 
depend on the type and age of neurons. Neural Plast 2016:5056418.
Kolman A (2004) Epothilone D (Kosan/Roche). Curr Opin Investig Drugs 5:657-667.
Li H, Wu W (2017) Microtubule stabilization promoted axonal regeneration and 
functional recovery after spinal root avulsion. Eur J Neurosci 46:1650-1662.
Mao L, Gao W, Chen S, Song Y, Song C, Zhou Z, Zhao H, Zhou K, Wang W, Zhu K, Liu C, Mei 
X (2017) Epothilone B impairs functional recovery after spinal cord injury by increasing 
secretion of macrophage colony-stimulating factor. Cell Death Dis 8:e3162.
Morganti-Kossmann MC, Semple BD, Hellewell SC, Bye N, Ziebell JM (2019) The 
complexity of neuroinflammation consequent to traumatic brain injury: from research 
evidence to potential treatments. Acta Neuropathol 137:731-755.
Ng SY, Lee AYW (2019) Traumatic brain injuries: pathophysiology and potential 
therapeutic targets. Front Cell Neurosci 13:528.
Ritzel RM, Doran SJ, Glaser EP, Meadows VE, Faden AI, Stoica BA, Loane DJ (2019) Old 
age increases microglial senescence, exacerbates secondary neuroinflammation, and 
worsens neurological outcomes after acute traumatic brain injury in mice. Neurobiol 
Aging 77:194-206.
Ruschel J, Bradke F (2018) Systemic administration of epothilone D improves functional 
recovery of walking after rat spinal cord contusion injury. Exp Neurol 306:243-249.
Ruschel J, Hellal F, Flynn KC, Dupraz S, Elliott DA, Tedeschi A, Bates M, Sliwinski C, Brook 
G, Dobrindt K, Peitz M, Brustle O, Norenberg MD, Blesch A, Weidner N, Bunge MB, 
Bixby JL, Bradke F (2015) Axonal regeneration. Systemic administration of epothilone 
B promotes axon regeneration after spinal cord injury. Science 348:347-352.
Sandner B, Puttagunta R, Motsch M, Bradke F, Ruschel J, Blesch A, Weidner N (2018) 
Systemic epothilone D improves hindlimb function after spinal cord contusion injury 
in rats. Exp Neurol 306:250-259.
Sengottuvel V, Fischer D (2011) Facilitating axon regeneration in the injured CNS by 
microtubules stabilization. Commun Integr Biol 4:391-393.
Sengottuvel V, Leibinger M, Pfreimer M, Andreadaki A, Fischer D (2011) Taxol facilitates 
axon regeneration in the mature CNS. J Neurosci 31:2688-2699.
Smith DH, Hicks R, Povlishock JT (2013) Therapy development for diffuse axonal injury. J 
Neurotrauma 30:307-323.
Smith DH, Wolf JA, Lusardi TA, Lee VMY, Meaney DF (1999) High tolerance and delayed 
elastic response of cultured axons to dynamic stretch injury. J Neurosci 19:4263-4269.
Spain A, Daumas S, Lifshitz J, Rhodes J, Andrews PJ, Horsburgh K, Fowler JH (2010) Mild 
fluid percussion injury in mice produces evolving selective axonal pathology and 
cognitive deficits relevant to human brain injury.  J Neurotrauma 27:1429-1438.
Stocchetti N, Zanier ER (2016) Chronic impact of traumatic brain injury on outcome and 
quality of life: a narrative review. Crit Care 20:148.
Sun M, Brady RD, Casillas-Espinosa PM, Wright DK, Semple BD, Kim HA, Mychasiuk R, 
Sobey CG, O’Brien TJ, Vinh A, McDonald SJ, Shultz SR (2019) Aged rats have an altered 
immune response and worse outcomes after traumatic brain injury. Brain Behav 
Immun 80:536-550.
Sun M, McDonald SJ, Brady RD, Collins-Praino L, Yamakawa GR, Monif M, O’Brien TJ, 
Cloud GC, Sobey CG, Mychasiuk R, Loane DJ, Shultz SR (2020) The need to incorporate 
aged animals into the preclinical modeling of neurological conditions. Neurosci 
Biobehav Rev 109:114-128.
Tang-Schomer MD, Patel AR, Baas PW, Smith DH (2010) Mechanical breaking of 
microtubules in axons during dynamic stretch injury underlies delayed elasticity, 
microtubule disassembly, and axon degeneration. FASEB J 24:1401-1410.
Wang H, Xiao C, Dong D, Lin C, Xue Y, Liu J, Wu M, He J, Fu T, Pan H, Jiao X, Lu D, Li Z 
(2018) Epothilone B speeds corneal nerve regrowth and functional recovery through 
microtubule stabilization and increased nerve beading. Sci Rep 8:2647. 
Wang HC, Ma YB (2010) Experimental models of traumatic axonal injury. J Clin Neurosci 
17:157-162.
Webster KM, Sun M, Crack PJ, O’Brien TJ, Shultz SR, Semple BD (2019) Age-dependent 
release of high-mobility group box protein-1 and cellular neuroinflammation after 
traumatic brain injury in mice. J Comp Neurol 527:1102-1117.
Yang Y, Zhang X, Ge H, Liu W, Sun E, Ma Y, Zhao H, Li R, Chen W, Yuan J, Chen Q, Chen Y, 
Liu X, Zhang JH, Hu R, Fan X, Feng H (2018) Epothilone B benefits nigrostriatal pathway 
recovery by promoting microtubule stabilization after intracerebral hemorrhage. J Am 
Heart Assoc 7:e007626. 
Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AML, Xie SL, Ballatore C, 
Smith AB, Lee VMY, Brunden KR (2012) The microtubule-stabilizing agent, epothilone 
D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-
like pathology in an interventional study with aged tau transgenic mice. J Neurosci 
32:3601-3611.
Zhao W, Chai Y, Hou Y, Wang DW, Xing JQ, Yang C, Fang QM (2017) Mechanisms 
responsible for the inhibitory effects of epothilone B on scar formation after spinal 
cord injury. Neural Regen Res 12:478-485.
 Zhu Z, Chuckowree JA, Musgrove R, Dickson TC, Blizzard CA (2020) The pathological 
outcomes and efficacy of epothilone treatment following traumatic brain injury is 
determined by age. Neurobiol Aging 93:85-96.
C-Editors: Zhao M, Li JY; T-Editor: Jia Y
Review
